Atipamezole Market to reach ~US$ 70 Mn by the end of 2030

High Preference for Injection Solutions to Minimize Sedative Effects of Medetomidine

Products that reduce sedative effects of medetomidine and dexmedetomidine are gauging high demand in the atipamezole market. Hence, companies are increasing their production capabilities to produce atipamezole products. For instance, Vetpharma-a part of the pharmaceutical ingredients company, Insud Pharma, is increasing its product portfolio in animal healthcare solutions by increasing the availability of Nosedorm, an effective atipamezole hydrochloride medicine. Such product innovations are bolstering the revenue of the atipamezole market, which is expected to reach ~US$ 70 Mn by the end of 2030.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111857

There is a growing demand for atipamezole drugs that facilitate swift reversal of sedatives. Apart from veterinary hospitals, pharmaceutical companies in the atipamezole market are tapping into incremental opportunities by strengthening their distribution networks with online pharmacies. Atipamezole solutions for injection are being highly preferred in dogs and cats. However, pet owners and veterinarians need to follow special precautions while using atipamezole medicines in animals.

Reduced Hospitalization Costs and In-clinic Stays Fueling Demand for Atipamezole Solutions

Increasing customer spending toward the ownership and adoption of pets is one of the key drivers that is catalyzing growth of the atipamezole market. Atipamezole hydrochloride sterile injectable solutions are creating revenue streams for pharmaceutical companies. The growing demand for dexmedetomidine and medetomidine reversing agents has fueled innovations in atipamezole drugs. Companies in the atipamezole market are increasing their R&D muscle for the production of anti-sedation agents. They are increasing awareness about safety data sheets to establish appropriate usage of atipamezole medicines in veterinary settings. For instance, Zoetis Services LLC- a global leader in animal healthcare solutions, is educating veterinary doctors about recommended uses and restrictions of ANTISEDAN®, a atipamezole hydrochloride injectable solution meant for only animal use.

Advantageous benefits of atipamezole such as shortening of in-clinic stays and reduced hospitalization costs are generating value-grab opportunities for companies in the atipamezole market. Safe and reliable reverse of dexmedetomidine hydrochloride has become increasingly important in veterinary systems. Hence, manufacturers are increasing their research efforts to develop improved formulations of atipamezole solutions.

Atipamezole Being Used to Study Effects of Sleep-inducing Substances in Humans

Apart from animal applications, atipamezole is being used to study the effects of sleep-inducing drugs in humans, due to the high prevalence of insomnia in adults. It has been found that atipamezole offsets the effectiveness of chlorpromazine and brotizolam. Hence, pharmaceutical companies in the atipamezole market are increasing their clinical trials in mice to validate the efficacy of atipamezole in humans.

Get a glimpse of the in-depth analysis through our Report Brochure

Since chlorpromazine and brotizolam result in delayed recovery from different types of anesthesia, atipamezole medicines hold promising potentials in rapid recovery from anesthesia. As such, adults are susceptible of developing at least one symptom of insomnia during various stages of their lifetime.

Awareness about Special Precautions Help Enhance Clinical Outcomes in Animals

Though atipamezole is considered as a reliable anti-sedation agent, complications such as hypersensitivity toward atipamezole in cats and dogs is a major concern for pharmaceutical companies. This explains the CAGR of ~1% of the atipamezole market. Moreover, atipamezole has been prohibited for use in breeding animals. Hence, companies in the atipamezole market are educating pet owners and veterinarians about special precautions and potential adverse effects of atipamezole in order to enhance clinical outcomes.

Pharmaceutical companies are focusing on increasing the application of atipamezole in animals that are given injectable anesthetics. Though inhalational anesthetics are an alternative to injectable anesthetics, the latter is useful when a large number of animals need to be anesthetized. In such cases, atipamezole is found to have a high efficacy in rapidly reversing the effects of anesthetics. This trend is peculiar in the combination of medetomidine, midazolam, and butorphanol (MMB) anesthetics for animals.

High Tolerance of Atipamezole in Healthy Dogs Boosts Product Uptake

Atipamezole hydrochloride is being highly publicized as a sterile injectable solution for intramuscular use in dogs. This is evident since the revenue of intramuscular route of administration is projected for exponential growth in the atipamezole market. As such, veterinarian doctors are taking extra precautions to determine the appropriate injection volume to reduce the incidence of adverse effects in animals. Companies in the atipamezole market are increasing awareness about contraindications in order to enhance clinical numbers in veterinary hospitals. As such, the revenue of veterinary hospitals is predicted for aggressive growth in the atipamezole market.

The demand for atipamezole medications is anticipated to gain steady growth, since the efficacious drug is well tolerated in healthy dogs. Quick reversal of sedatives after atipamezole dosage frees up veterinarian and staff, resulting in increased productivity levels in clinical settings. Thus, effective animal care is restoring the faith of pet owners. Efficacious atipamezole medications help to avoid the hassles associated with return trips to veterinary clinics.

Growing Need for Animal Care amidst COVID-19 Pandemic Fuels Demand for Atipamezole

The novel coronavirus (COVID-19) has caused a global economic slowdown. COVID-19 has exposed the vulnerability of healthcare systems and veterinary hospitals. Scarcity in resources for human treatment has caused a negative impact in the animal healthcare domain. Hence, companies in the atipamezole market are increasing their efforts to maximize their production capabilities to manufacture anti-sedative drugs for animals. However, logistics and transportation regulations pertaining to raw material supply due to lockdown scenarios pose a challenge for companies in the atipamezole market. As such, partial and complete lifting of lockdown in various countries of Asia Pacific has helped pharmaceutical companies to resume production activities.

Analysts’ Viewpoint

Since pet owners are finding it difficult to receive quality animal healthcare services amidst the COVID-19 pandemic, companies are increasing efforts to stabilize the situation by producing atipamezole medications to avoid supply shocks in veterinary clinics. The demand for sterile injectable solutions is gauging a steady growth in the atipamezole market.

Atipamezole is acquiring prominence in undergraduate pharmacology training programs to assess its effectiveness against MMB in insomnia patients. However, there is a need for further studies to classify the potentials of atipamezole in sleep-inducing drugs for insomnia patients. Hence, companies should increase their focus in isoflurane inhalation to innovate in new atipamezole medications.

Atipamezole Market: Overview

The global atipamezole market for the historical period 2018–2019 and forecast period 2020–20230, increase in healthcare expenditure on animals boosts the global atipamezole market

Atipamezole is a veterinary medicine primarily utilized to reverse the sedative and analgesic effects. Additionally, it is used as an antidote for various toxicities in dogs. Atipamezole received license in the U.S. for intramuscular use in dogs. However, it is used off-label in cats and other animals such as horses and cows, rabbit, etc.

Increase in Awareness about Veterinary Care to Drive Atipamezole Market

Awareness about animal disease, their symptoms, and medication is most important for pet or livestock owners. Several animal health awareness programs have been conducted to increase awareness among people. For instance, the Agriculture and Animal Health Awareness Programme was organized at Panchot GP, Gujarat, India, to raise awareness among people regarding animal healthcare and generate employment, and to take care of animal health. Government and private sector organizations are engaged in spreading awareness about the importance of animal care. For instance, The American Animal Hospital Association is a non-profit organization for companion animal veterinary hospitals. It is an accrediting body for small animal hospitals in the U.S. and Canada. Increase in awareness about veterinary health is anticipated to drive the atipamezole market.

Increase in Pet Ownership and Pet Adoption to Propel Atipamezole Market

Since ancient times, pets, particularly dogs, have found favor as a companion across the world. Pets have evolved from being a strange and wonderful distraction to an integral part of families all over the world. For instance, according to a survey conducted by American Pet Products Association (APPA), in 2018, the U.S. had approximately 90 million pet dogs.

Per owners are increasingly treating their cats, dogs, and small mammals like family members. Thus, the number of pet owners and pet adoption is increasing. This, in turn, is estimated to boost the atipamezole market.

Stringent Government Regulations to Hamper Atipamezole Market

New animal drugs are approved on the basis of safety and efficacy regulations; however, stringent regulations enacted by governments may hamper industry players. Furthermore, new and more stringent regulations indirectly or directly impact the usage of products. The animal health business is affected by several factors including regulatory and legislative issues.

Hence, stringent government regulations associated with safety and efficacy are likely to hamper the atipamezole market

Atipamezole Market: Competition Landscape

This report profiles major players operating in the global atipamezole market based on various attributes and recent developments

The global atipamezole market is highly fragmented, with the presence of numerous international as well as regional players

Leading players operating in the global atipamezole market include 

• Zoetis Services LLC
• Merck & Co., Inc. (Merck Sharp & Dohme Corp)
• Modern Veterinary Therapeutics
• Orion Corporation
• Jurox Pty Limited
• Vetoquinol UK Limited
• Chanelle Pharma Group
• Forte Healthcare Ltd
• Troy Laboratories Pty Ltd

Key Questions Answered in Atipamezole Market Report

• What is the scope of growth for product companies in the global atipamezole market?
• What will be the Y-o-Y growth of the global atipamezole market between 2020 and 2030?
• What is the influence of changing trends in technologies on the global atipamezole market?
• Will North America continue to be the most profitable market for atipamezole?
• Which factors are anticipated to hamper the growth of the global atipamezole market during the forecast period?
• Which are the leading companies in the global atipamezole market?

Atipamezole Market – Segmentation

Application

• Anti-sedative
• Antitoxic (Off-label Use)

Route of Administration

• Intramuscular
• Intravenous
• Others

Animal Type

• Dogs
• Cats
• Others

Distribution Channel

• Veterinary Hospitals
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111857/2900